Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program

Fibrocor Therapeutics Canada Massachusetts California

Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1bDeal is a major step forward for Fibrocor's plans to develop FIB918, its monoclonal antibody for Alport Syndrome, a rare disease with very limited treatment optionsFibrocor and MSRD intend to start Phase 1 clinical trials of its monoclonal antibody in 2025View original content:https://www.prnewswire.co.uk/news-releases/fibrocor-therapeutics-enters-into-research-and-development-collaboration-with-mcquade-center-for-strategic-research-and-development-to-advance-alport-syndrome-program-302078803.html